Core Insights - Microbix Biosystems Inc. will present its H5N1 pandemic preparedness results at the ADLM conference in Chicago from July 28 to 31, 2025 [1][2] - The company will showcase its quality assessment products (QAPs™) that ensure the accuracy of antigen and molecular tests [2][3] - A pilot External Quality Assessment (EQA) program will be presented, focusing on the detection of the H5N1 strain using existing molecular tests [3][4] Company Overview - Microbix is a life sciences innovator with over 120 employees and aims for revenues of C$ 2.0 million or more per month [6] - The company specializes in proprietary biological products for human health, including antigens for immunoassays and QAPs that support clinical lab proficiency testing [6][7] - Microbix's QAPs are available in over 30 countries and are supported by a network of international distributors [6] Product Development - The H5N1 QAPs were developed to ensure full genetic coverage of potential pandemic strains and are available in liquid and FLOQSwab formats [5] - The collaboration with American Proficiency Institute (API) is crucial for evaluating the performance of flu tests in detecting H5N1 [4][5] - The company emphasizes the rapid deployment of its capabilities in response to emerging pandemics [5]
Microbix Exhibiting & Presenting at ADLM